Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3238 studies found for:    non-Hodgkin's lymphoma
Show Display Options
Download search resultsDownload the search results for:
non-Hodgkin's lymphoma (3238 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Completed Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Iodine I 131 Tositumomab
2 Completed Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: bendamustine hydrochloride
3 Completed Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America
Conditions: Multiple Myeloma;   Leukemia;   Lymphoid;   Lymphoma;   Non-Hodgkin
Interventions: Other: Chronic Lymphocytic Leukemia (CLL);   Other: Multiple Myeloma (MM);   Other: Non-Hodgkin's lymphoma (NHL)
4 Active, not recruiting A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: ABT-199;   Drug: Bendamustine;   Drug: Rituximab
5 Completed A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Everolmus
6 Completed SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: bendamustine and rituximab
7 Completed
Has Results
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Oxaliplatin
8 Completed Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era
Condition: Non-Hodgkin's Lymphoma
Intervention:
9 Completed
Has Results
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Bortezomib + Rituximab;   Drug: Rituximab
10 Unknown  Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: bortezomib, tositumomab
11 Completed Interdisciplinary Case-Control Study of Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention:
12 Withdrawn A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
Condition: Relapsed/Refractory Non-Hodgkin's Lymphoma
Intervention: Drug: [14C]ABT-199 (GDC-0199)
13 Recruiting Diagnostic Qualities of the Positron Emission Tomography Coupled to the Scanner (PET / CT) in the Assessment of Response to Non-Hodgkin's Lymphoma Therapy in Children and Adolescents
Condition: Non-Hodgkin Lymphoma
Intervention: Device: PET / CT
14 Completed Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: SDX-105
15 Recruiting A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
Condition: Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
Interventions: Drug: Imprime PGG;   Drug: Rituximab
16 Recruiting Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Lenalidomide/Rituximab
17 Recruiting Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma
Condition: Non Hodgkin's Lymphoma
Interventions: Drug: Rituximab;   Drug: Lenalidomide
18 Completed
Has Results
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Conditions: Low-grade B Cell Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated
Interventions: Drug: SyB L-0501;   Drug: rituximab
19 Terminated
Has Results
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma
Condition: T-cell Non-Hodgkin's Lymphoma
Intervention: Drug: Lenalidomide
20 Unknown  Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Dasatinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.